Larger trim than 25-33%, retain exposure below 2%, exit re-entry plan until Q3 prints, use protective puts through earnings window, tighten stop to close below 10 EMA at 212.54

• 5-year stock return: negative 23.5 percent versus S&P 500 ~90 percent and Nasdaq >100 percent over same period
• Price at 213.56, currently $1 above 10 EMA at 212.54
• 50 SMA at 198.89, 200 SMA at 202.47
• MACD histogram at approximately 0.43
• Structural margin compression: 920 basis points
• ROE: 7.6 percent
• Intangibles on balance sheet: 73 percent
• Trailing PE: 38 times
• Forward PE: 22.97
• Higher-for-longer rate scenario: 88 percent probability priced on zero cuts in 2026
• Stop level at 200 from 213.56 entry is roughly 2.2 ATR
• QDEL cutting 2026 guidance on China and respiratory demand cited as direct competitor signal for DHR end markets
• Aggressive analyst trim recommendation: 25 to 33 percent
• Aggressive analyst re-entry levels: above 222.21 or at 195 to 200 pullback
• Conservative recommends removing pre-committed re-entry levels entirely
• Conservative prefers Q3 to print before re-engaging with position

→ vs aggressive: Aggressive analyst undersells remaining risk by recommending only 25-33% trim when fundamentals show -23.5% five-year return, 920 bps margin compression, 7.6% ROE, and 73% intangibles; 2-3% retained exposure is not a rounding error in an institutional book

→ vs aggressive: Aggressive analyst's re-entry plan at 222.21 or 195-200 is anchoring to round numbers on a fundamentally challenged name; a conservative should stay out for quarters, not weeks, and not pre-commit to reload zones on a stock with structural headwinds

→ vs aggressive: Aggressive analyst only partially addressed second-order macro risk; if 10-year pushes through 4.5% on no-cut regime, duration-sensitive capital rotates out of DHR's defensiveness causing multiple compression independent of bioprocessing cycle

→ vs neutral: The 'healthcare compounder to watch' narrative makes people comfortable doing nothing at 213.56 after a 22% three-month rally; this is precisely when complacency gets expensive

Trim 25-33% to 2-3% exposure; hold protective put spread; use conditional re-entry triggers at $222.21 breakout or $195-200 pullback; don't pre-commit to Q3 exit or reload

• Price sitting above 50 SMA that stair-stepped from 178 to 198 over six weeks, and above 200 SMA that has just turned up
• MACD is positive and rising, RSI at 60, 22 percent recovery in 90 days with moving averages aligned bullish
• Veralto spin-off and 920 basis point margin normalization from peak drove 5-year underperformance, not structural operating model failure
• DHR is a 150 billion dollar market cap company with 4.3 billion in trailing free cash flow, 0.53 times debt to equity, 0.80 beta, and 50 percent recurring consumables revenue
• Recommend trimming to 2-3 percent cap rather than going below 1.5 percent or exiting entirely
• Stop at 200 serves as hard floor; add dynamic tightening rule if 10 EMA at 212.54 closes below ahead of Q3
• Structural put spread: buy 200 put, sell 180 put for 20 points of downside protection at roughly half the cost of naked 200 put
• 88 percent no-cut probability is already priced in, not new information; 8 percent recession odds are benign
• 0.80 beta, FCF, and recurring revenue base mean stock does not require multiple expansion in higher-for-longer regime
• 6.2 sentiment score with low confidence is a yellow light, not green; argues for waiting on Q3 catalyst
• Conservative analyst's pre-commitment to stay out for quarters is an anchoring error; aggressive analyst anchored to trough numbers as if permanent

→ vs aggressive: Five-year comparison captures COVID bubble peak, post-COVID destocking, Veralto spin-off, and 920 bps margin normalization—not a fair structural read; 22 percent recovery with aligned moving averages is not a 'run for the exits' setup

→ vs conservative: Full exit throws away a quality franchise on cyclical timing; 2-3 percent position maintains upside participation in bioprocessing inflection while capping downside; below 1.5 percent is basically being out

→ vs conservative: Protective put is insurance with positive expected value given binary catalyst, not an expensive cost to avoid; put spread structure reduces premium drag while maintaining protection